In brain, monoamine transporters are principal targets of widely used
therapeutic drugs including antidepressants, methylphenidate (Ritalin)
, and the addictive drug cocaine. Without exception, these transport b
locking agents contain an amine nitrogen. A prevalent view and unteste
d premise is that an amine nitrogen is needed to bind to the same coun
terion on the transporter as does the amine nitrogen of the monoamine
neurotransmitter. We report that several compounds without nitrogen (8
-oxa-biyclo-3-aryl-[3.2.1] octanes, or aryloxatropanes) are active at
monoamine transporters. One of these, tropoxane (O-914), bound with hi
gh affinity to the dopamine (IC50: 3.35 +/- 0.39 nM), serotonin (IC50:
6.52 +/- 2.05 nM), and norepinephrine (IC50: 20.0 +/- 0.3 nM) transpo
rters in monkey brain, the human striatal dopamine transporter (IC50:
5.01 +/- 1.74 nM), and blocked dopamine transport (IC50: 7.2 +/- 3.0 n
M) in COS-7 cells transfected with the human dopamine transporter. The
se unique compounds require a revision of current concepts of the drug
binding domains on monoamine transporters, open avenues for discovery
of a new generation of drugs and raise the issue of whether mammalian
transporters and receptors may respond to, as yet, undiscovered non-a
mine bearing neurotransmitters. (C) 1996 Wiley-Liss, Inc.